Doctor Up Your Portfolio With This Medical Communications Company

by Louise Harris, Investment U Research

The healthcare reform debate continues to swirl in Washington. And Marc Lichtenfeld and Louis Basenese have discussed this crucial topic recently, offering their thoughts on the companies best positioned to profit.

That’s because regardless of the back-and-forth and political slanging match, the healthcare sector still offers strong potential for solid returns, due to skyrocketing demand.

In particular, one small-cap poised for gains is the Utah-based firm ZYTO Corp. (OTC: ZYTC). It focuses on medical communication software and services, including an operating system that transfers information from computers to humans.

But ZYTO goes beyond simple data input. It uses patent-pending methods that monitor biological states in near-real time, creating a stimulus-response experience called a bio-survey.

(Translation: It reads life signs and converts them into easily readable

...

The NCOA (National Council On Aging) announced that they have added Sanofi-Aventis U.S. to their list of growing sponsors for BenefitsCheckUp program. NCOA has many companies and firms on the list of sponsors for this program and Sanofi-Aventis joins the 20 other sponsors that include pharmaceutical companies, healthcare organizations, government partners, health foundations and corporations. In an announcement to the media, President and CEO of Sanofi-Aventis U.S., Greg Irace said that they are proud to join NCOA in this important initiative to provide help to older adults of America where they can receive health care benefits that they deserve.

Sanofi-Aventis is a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to improve the lives of patients all around the world. The National Council On Aging is a nonprofit service

...

QuantRx Biomedical Corp., a diagnostic company focused on developing and commercializing innovative diagnostic products, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent extending its lateral flow testing intellectual property suite. This new patent will add significant protection as QuantRx enters the market with its hypersensitive point-of-care lateral flow based system. Together with the patented Q-reader technology, QuantRx is able to provide CLIA (Clinical Laboratory Improvement Amendments) waived Point-of-Care (POC) tests that other technologies cannot offer.

“This milestone event for QuantRx marks the culmination of over a decade of research by our exceptional R&D team,” stated Dr. William Fleming, President of Diagnostics at QuantRx. “RapidSense® with its exceptional low level sensitivity, coupled with our unique device technology, allows QuantRx to capitalize on its knowledge base to create tests that, until now, have been limited to laboratory or simple qualitative testing. QuantRx believes that it

...

Hologic Inc., a diversified diagnostic and medical product and device company, works with its subsidiaries to develop, manufacture and distribute medical imaging systems and surgical products designed to serve the healthcare needs of women. The Company’s core business units are focused on breast health, diagnostics, GYN surgical and skeletal health.

The Breast Health segment offers a broad portfolio of breast imaging and related products. The Diagnostic Products segment provides ThinPrep System, cervical cancer screening and Fetal Fibronectin Test for pre-term birth risk assessment. The GYN Surgical segment includes NovaSure Impedance Controlled RF Ablation system, a minimally-invasive procedure that allows physicians to treat women suffering from excessive menstrual bleeding. The Skeletal Health Segment includes dual-energy X-ray bone densitometers and ultrasound bone analyzers that address a growing market for osteoporosis prevention and treatment.

In October 2007, HOLX acquired Cytyc Corporation for approximately $6.2 billion to become one of the largest companies in the

...

Hologic Inc. (HOLX) is a developer, manufacturer, and supplier of medical imaging systems and diagnostic and surgical products focused on the healthcare needs of women. Historically, the company has developed, manufactured, and marketed products focused on mammography, breast care and osteoporosis assessment.HOLX reported Q4 EPS that were in-line to our estimate on revenue that exceeded our forecast. We lowered our FY09 revenue and EPS estimates to within the initial management guidance. We initiated our FY10 revenue and EPS estimates. Our price target is based on a P/E multiple of roughly 11x 2009 EPS estimate.The acquisition of Third Wave Technologies is expected to dilute FY08 and FY09 EPS and be accretive thereafter. Execution risk exists related to the integration of the two acquisitions and completion and transfer of surgical manufacturing to the lower cost Costa Rica plant. Uncertainty exists to revenue growth as a result ...

Hologic, Inc. (HOLX) is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic’s core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. The company, in June, announced the acquisition of Third Wave Technologies, which developed and marketed molecular diagnostic reagents for a wide variety of DNA and RNA analysis applications based on its proprietary Invader® chemistry.

Hologic recently announced it is the first diagnostic medical device manufacturer to receive U.S. Food and Drug Administration clearance to incorporate the World Health Organization (WHO) FRAX™ 10-year fracture risk calculator into its bone densitometer systems. The WHO Collaborating Centre for Metabolic Bone Diseases, located at the University of Sheffield Medical School, U.K., developed FRAX as a tool to help healthcare providers identify and proactively treat patients with a high risk of bone

...